1. Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997; 17:15–22.
2. Takeshima T, Ishizaki K, Fukuhara Y, Ijiri T, Kusumi M, Wakutani Y, et al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache. 2004; 44:8–19.
Article
3. Ishii M, Sakairi Y, Hara H, Imagawa A, Shimizu S, Takahashi J, et al. Negative predictors of clinical response to triptans in patients with migraine. Neurol Sci. 2012; 33:453–461.
Article
4. Onaya T, Ishii M, Katoh H, Shimizu S, Kasai H, Kawamura M, et al. Predictive index for the onset of medication overuse headache in migraine patients. Neurol Sci. 2013; 34:85–92.
Article
5. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012; 78:1346–1353.
Article
6. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012; 78:1337–1345.
Article
7. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009; 16:968–981.
Article
8. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia. 1992; 12:81–84.
Article
9. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995; 52:281–286.
Article
10. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache. 2006; 46:642–648.
Article
11. Takeshima T, Nishikawa W, Yoneda H, Kanki R, Yamashita S, Kikui S. Efficacy and safety of valproate in a series of Japanese migraine sufferers (in Japanese). Japanese J Headache. 2013; 39:306–311.
12. Géraud G, Lantéri-Minet M, Lucas C, Valade D. French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther. 2004; 26:1305–1318.
Article
13. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24:Suppl 1. 9–160.
14. Headache Classification Committee. Olesen J, Bousser MG, Diener HC, Dodick D, First M, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006; 26:742–746.
Article
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association;1994.
16. Erdemoglu AK, Ozbakir S. Valproic acid in prophylaxis of refractory migraine. Acta Neurol Scand. 2000; 102:354–358.
Article
17. Ishii M, Katoh H, Kurihara T, Kawamura M, Shimizu S. Characteristics of inconsistent responders to prophylaxis therapy with lomerizine in patients with migraine: a retrospective study in Japan. J Neurol Sci. 2013; 335:118–123.
Article
18. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates;1988.
19. Ishii M, Shimizu S, Sakairi Y, Nagamine A, Naito Y, Hosaka Y, et al. MAOA, MTHFR, and TNF-β genes polymorphisms and personality traits in the pathogenesis of migraine. Mol Cell Biochem. 2012; 363:357–366.
Article
20. Silberstein SD. Preventive migraine treatment. Neurol Clin. 2009; 27:429–443.
Article
21. Kinze S, Clauss M, Reuter U, Wolf T, Dreier JP, Einhäupl KM, et al. Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study. Headache. 2001; 41:774–778.
Article
22. Chen YC, Tang CH, Ng K, Wang SJ. Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan. J Headache Pain. 2012; 13:311–319.
Article
23. Tana C, Santilli F, Martelletti P, di Vincenzo A, Cipollone F, Davì G, et al. Correlation between migraine severity and cholesterol levels. Pain Pract. 2015; 15:662–670.
Article
24. Sener A, Ozsavci D, Oba R, Demirel GY, Uras F, Yardimci KT. Do platelet apoptosis, activation, aggregation, lipid peroxidation and platelet-leukocyte aggregate formation occur simultaneously in hyperlipidemia? Clin Biochem. 2005; 38:1081–1087.
Article
25. Sarchielli P, Gallai V. Platelets in migraine. J Headache Pain. 2001; 2:Suppl 1. S61–S66.
Article
26. Buettner C, Burstein R. Association of statin use and risk for severe headache or migraine by serum vitamin D status: a cross-sectional population-based study. Cephalalgia. 2015; 35:757–766.
Article
27. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol. 1984; 16:157–168.
Article
28. Andersson M, Svensson C, Andersson P, Pipkorn U. Objective monitoring of the allergic inflammatory response of the nasal mucosa in patients with hay fever during natural allergen exposure. Am Rev Respir Dis. 1989; 139:911–914.
Article
29. Aamodt AH, Stovner LJ, Langhammer A, Hagen K, Zwart JA. Is headache related to asthma, hay fever, and chronic bronchitis? The Head-HUNT Study. Headache. 2007; 47:204–212.
Article